251 related articles for article (PubMed ID: 35476308)
1. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
Martin ; Zhou Y; Takagi T; Tian YS
Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308
[TBL] [Abstract][Full Text] [Related]
2. Effects of Switching from Degludec to Glargine U300 in Patients with Insulin-Dependent Type 1 Diabetes: A Retrospective Study.
Sawamura T; Karashima S; Ohbatake A; Higashitani T; Ohmori A; Sawada K; Yamamoto R; Kometani M; Katsuda Y; Yoneda T
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541176
[No Abstract] [Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
5. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
Martin ; Zhou Y; Takagi T; Tian YS
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
[TBL] [Abstract][Full Text] [Related]
7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Zhang XW; Zhang XL; Xu B; Kang LN
Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
Joshi SR; Singh G; Marwah A; Mittra S; Suvarna VR; Athalye SN
Diabetes Obes Metab; 2023 Jun; 25(6):1589-1606. PubMed ID: 36748186
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
[TBL] [Abstract][Full Text] [Related]
12. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
13. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
[TBL] [Abstract][Full Text] [Related]
14. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
[No Abstract] [Full Text] [Related]
15. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Dong ZY; Feng JH; Zhang JF
Clin Ther; 2022 Nov; 44(11):1520-1533. PubMed ID: 36763996
[TBL] [Abstract][Full Text] [Related]
16. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
[TBL] [Abstract][Full Text] [Related]
17. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
[TBL] [Abstract][Full Text] [Related]
18. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
19. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
20. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]